Scarica l'app Stockscreener
127.59
0.05%
-0.1641
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$127.75
Aprire:
$127.5
Volume 24 ore:
133.00K
Relative Volume:
0.09
Capitalizzazione di mercato:
$18.75B
Reddito:
$9.82B
Utile/perdita netta:
$1.48B
Rapporto P/E:
12.59
EPS:
10.13
Flusso di cassa netto:
$2.30B
1 W Prestazione:
-3.23%
1M Prestazione:
-5.03%
6M Prestazione:
-9.66%
1 anno Prestazione:
-37.43%
Intervallo 1D:
$127.00
$128.78
Intervallo di 1 settimana:
$127.00
$134.16
Portata 52W:
$110.03
$207.59
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
127.91 | 18.96B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
625.87 | 670.04B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
172.75 | 410.84B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
197.45 | 346.78B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
116.37 | 219.72B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.61 | 198.42B | 63.62B | 16.41B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Headlands Technologies LLC Sells 3,608 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
iA Global Asset Management Inc. Acquires 2,636 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Arkadios Wealth Advisors Purchases Shares of 3,354 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Position Cut by J. Safra Sarasin Holding AG - MarketBeat
Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease - Seeking Alpha
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment? - TipRanks
We Think Biogen's (NASDAQ:BIIB) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Primecap Management Co. CA Lowers Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Bank of Nova Scotia Sells 4,241 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Natixis Advisors LLC Acquires 9,946 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
What is William Blair's Forecast for Biogen Q2 Earnings? - MarketBeat
Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates - MSN
Japan OKs Price Cut for Alzheimer's Drug Lecanemab - JIJI PRESS
US Bancorp DE Has $3.55 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cantor Fitzgerald Brokers Lift Earnings Estimates for Biogen - MarketBeat
Biogen (NASDAQ:BIIB) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Biogen (NASDAQ:BIIB) Price Target Raised to $135.00 at Citigroup - MarketBeat
Biogen (BIIB) Price Target Hiked to $130 at UBS amid Leqembi Development - MSN
Spinal Muscular Atrophy Market Opportunities and Future Scope - openPR.com
Fund Update: STATE OF MICHIGAN RETIREMENT SYSTEM added 251,600 shares of BIOGEN ($BIIB) to their portfolio - Quiver Quantitative
LSV Asset Management Grows Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Y Intercept Hong Kong Ltd Sells 13,310 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Royal Bank Of Canada Issues Positive Forecast for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
HC Wainwright Issues Positive Forecast for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
Spinal Muscular Atrophy Pipeline Outlook 2025: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight - Barchart.com
Biogen Inc. (BIIB): A Bull Case Theory - Insider Monkey
Biogen moving ‘rapidly’ in quest to bring salanersen to SMA patients - SMA News Today
BofA Lowers PT on Biogen (BIIB) to $142 From $143, Keeps a Neutral Rating - Insider Monkey
Chronic Lymphocytic Leukemia Therapeutics Market is Fueled - openPR.com
Banco Santander S.A. Purchases 7,182 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen is building a ‘ventures’ team to ‘keep early portfolio externalized’ - Endpoints News
Reversal Confirmed Biogen Inc. Stock Rallies Above MAReal-Time Trade Insights Spark Market Reactions - beatles.ru
Biogen (NASDAQ:BIIB) Updates FY 2025 Earnings Guidance - MarketBeat
Nicolet Advisory Services LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen's Earnings Beat and Leqembi Progress Might Change The Case For Investing In BIIB - simplywall.st
Biogen Stock (BIIB): Strong Q2 Performance Fuels Growth - Value The Markets
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - MSN
Wedbush Forecasts Biogen's Q3 Earnings (NASDAQ:BIIB) - MarketBeat
Leerink Partnrs Estimates Biogen's Q3 Earnings (NASDAQ:BIIB) - MarketBeat
Tredje AP fonden Purchases New Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Banque Cantonale Vaudoise Invests $1.35 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
XTX Topco Ltd Buys 14,459 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
When is Biogen Inc. stock expected to show significant growthAchieve breakthrough profits with smart strategies - Jammu Links News
What drives Biogen Inc. stock priceAchieve rapid portfolio appreciation - jammulinksnews.com
11 Cheap Pharmaceutical Stocks to Buy Now - Insider Monkey
How does Biogen Inc. compare to its industry peersGet daily expert analysis for smarter investing - Jammu Links News
Biogen (NASDAQ:BIIB) Releases Earnings Results, Beats Expectations By $1.54 EPS - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Boosted by R Squared Ltd - MarketBeat
Jefferies Financial Group Inc. Has $6.84 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
0.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):